Medications
Nutrition guidance for
every GLP-1 medication.
Each medication has its own pharmacology, side-effect profile, and dose schedule. So does its nutrition strategy. Pick yours below.
Four brands, two molecules. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. Within a pair the chemistry is identical — what changes is the licence, and that changes more than paperwork. A drug approved for type 2 diabetes is taken by a different population, titrated against different goals, and paid for under different rules than the same compound approved for weight management.
So the useful question is rarely “which is best”. It is which one you are holding, what it is licensed for where you live, and how high its ladder goes — because the ceiling, not the brand, is what sets how fast weight comes off and therefore how hard your protein target becomes.
Mounjaro
tirzepatide · Once-weekly subcutaneous injection
Mounjaro is a once-weekly injectable for adults with type 2 diabetes. The active ingredient, tirzepatide, is the first dual GLP-1/GIP receptor agonist — it activates BOTH gut hormone receptors involved in glucose and appetite regulation. This dual action makes it more potent than semaglutide-based drugs (Ozempic, Wegovy).
Read nutrition guide →
Ozempic
semaglutide · Once-weekly subcutaneous injection
Ozempic is a once-weekly injectable medication for adults with type 2 diabetes. The active ingredient, semaglutide, is a GLP-1 receptor agonist — it mimics a hormone your gut produces after eating. Although Ozempic is FDA-approved for blood sugar control, it's widely prescribed off-label for weight management because of its powerful appetite-suppressing effect.
Read nutrition guide →
Wegovy
semaglutide · Once-weekly subcutaneous injection
Wegovy is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults and adolescents (12+) with obesity or overweight with at least one weight-related condition. It contains the same active ingredient as Ozempic — semaglutide — but at a higher target dose (2.4 mg/week vs Ozempic's 2 mg ceiling).
Read nutrition guide →
Zepbound
tirzepatide · Once-weekly subcutaneous injection
Zepbound is a once-weekly injectable medication FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It contains tirzepatide — the same active ingredient as Mounjaro — but is FDA-approved at the higher doses (up to 15 mg) for weight loss specifically.
Read nutrition guide →
Every page, by medication